Taxanes are the most active drugs in the treatment of metastatic breast and ovarian cancer. Weekly therapy with paclitaxel produces notable activity, with remarkably low toxicity.
Hans-Joachim Lück, MD
Advertisement
Articles by Hans-Joachim Lück, MD
Paclitaxel (Taxol) is one of the most active drugs in the treatment of ovarian and breast cancers. Combination therapy with paclitaxel and 5-fluorouracil (5-FU) exhibits high activity in anthracycline-pretreated breast cancer,
This study evaluated the safety and feasibility of the combination of paclitaxel (Taxol) and epirubicin, the 4¢-epimer of doxorubicin, in women with metastatic breast cancer. A total of 85 patients with histologically proven
Paclitaxel (Taxol) has aroused considerable interest for its high single-agent activity in breast cancer and novel mechanism of action. Epirubicin (Farmorubicin), the 4'epimer of doxorubicin (Adriamycin), also has high activity in
Advertisement
Latest Updated Articles
- Metastatic Breast Cancer: Experience with the Combination Paclitaxel Plus Epirubicin
Published: January 1st 1998 | Updated:
- UFT/Leucovorin Combined With Paclitaxel for Anthracycline-Pretreated Advanced Breast Cancer
Published: October 1st 2000 | Updated:
- UFT/Oral Calcium Folinate Plus Weekly Paclitaxel for Metastatic Breast Cancer
Published: July 1st 1999 | Updated:
- Paclitaxel and Epirubicin as First-Line Therapy for Patients With Metastatic Breast Cancer
Published: April 1st 1997 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
3
BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer
4
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
5
